MedTrace Logo

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02556788 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1212

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

CD5789 (trifarotene) 50µg/g Cream

CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.

DRUG

Placebo Cream

Placebo cream applied once daily during 12 weeks.

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Kevin Chan · Galderma R&D

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-02-07
Completion
2017-05-12

Countries

  • United States
  • Czechia
  • Hungary
  • Poland
  • Romania
  • Russia
  • Spain
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556788 on ClinicalTrials.gov